These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22682792)

  • 1. Nifedipine XL-induced dysuria.
    Patil K; Tabibian JH; Lake M; Sisson S
    Am J Med; 2012 Sep; 125(9):e3-4. PubMed ID: 22682792
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-substitution of nifedipine slow-release preparations.
    Van Veenhuyzen D; Coetzee R
    S Afr Med J; 2002 Nov; 92(11):838, 840. PubMed ID: 12506575
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduced proteinuria after cessation of long-acting, osmotic release nifedipine GITS in diabetic nephropathy.
    Hess B
    Nephrol Dial Transplant; 1997 Aug; 12(8):1772-3. PubMed ID: 9269678
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of two formulations of nifedipine during 24-hour ambulatory blood pressure monitoring--a comment.
    Lucas BD; Hilleman DE; Wurdeman RL
    Pharmacotherapy; 1997; 17(4):853-4. PubMed ID: 9250574
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment with nifedipine retard: increasing doses as a therapeutic method].
    Lobos Berajano JM; Lahoz Rallo F; Seguido Aliaga P; Castellanos Maroto J; Robles Pérez R
    Rev Clin Esp; 1989 Jan; 184(1):47-9. PubMed ID: 2704870
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of sublingual nifedipine: a continuing concern.
    Messerli FH; Grossman E
    Arch Intern Med; 1999 Oct; 159(19):2259-60. PubMed ID: 10547164
    [No Abstract]   [Full Text] [Related]  

  • 7. [Slow release nifedipine in treatment of hypertension. 24-hour effect on blood pressure and heart rate--treatment follow-up of 391 patients].
    Bühler G; Wadepuhl M; Nandi K; Rosenthal J
    Fortschr Med; 1997 Aug; 115(24):37-8. PubMed ID: 9410819
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical features and up-to-date therapy of hypertensive emergencies].
    Meyer FP
    Dtsch Med Wochenschr; 2004 Apr; 129(14):768; author reply 768-9. PubMed ID: 15042498
    [No Abstract]   [Full Text] [Related]  

  • 9. Nifedipine in ischemic heart disease.
    Kloner RA
    Circulation; 1995 Sep; 92(5):1074-8. PubMed ID: 7648647
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of nifedipine on ocular pulse amplitude in normal pressure glaucoma].
    Schmidt KG; von Rückmann A; Geyer O; Mittag TW
    Klin Monbl Augenheilkd; 1997 Jun; 210(6):355-9. PubMed ID: 9333660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Am J Hypertens; 2008 Aug; 21(8):948-54. PubMed ID: 18600215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.
    Nakayama J; Koga T; Furue M
    Eur J Dermatol; 1998 Dec; 8(8):563-8. PubMed ID: 9889429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective controlled trial of two nifedipine extended release formulations in the treatment of essential hypertension.
    Pivac N; Naranca M; Vujic-Podlipec D; Bagatin J; Rumboldt Z
    Arzneimittelforschung; 2002; 52(5):379-84. PubMed ID: 12087923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral pathology case of the quarter.
    Houston GD
    J Okla Dent Assoc; 2001; 91(3):42-4. PubMed ID: 11314179
    [No Abstract]   [Full Text] [Related]  

  • 15. Nifedipine trials.
    Rafflenbeul W
    Circulation; 1996 Apr; 93(7):1473-4. PubMed ID: 8641042
    [No Abstract]   [Full Text] [Related]  

  • 16. Case presentation. Initiation of gingival overgrowth by an increased daily dosage of nifedipine.
    Henderson JS; Guillot JL; Krolls SO; Parkel CO; Johnson RB
    Miss Dent Assoc J; 1994; 50(3):12-3. PubMed ID: 9569836
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of the effects of two modified release preparations of nifedipine-nifedipine retard 10 mg twice daily and nifedipine GITS 20 mg once daily--in the treatment of mild to moderate hypertension.
    Kirby BJ; Kitchin NR
    Int J Clin Pract; 1999; 53(5):339-43. PubMed ID: 10695096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrections to the nifedipine meta-analysis.
    Furberg CD; Psaty BM
    Circulation; 1996 Apr; 93(7):1475-6. PubMed ID: 8641044
    [No Abstract]   [Full Text] [Related]  

  • 19. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
    Saito I; Saruta T;
    Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Another report of adverse reactions to immediate-release nifedipine.
    Fami MJ; Ho NT; Mason CM
    Pharmacotherapy; 1998; 18(5):1133-5. PubMed ID: 9758326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.